Trial
NCT05400577
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Fox Chase Cancer Center
Collaborators
—
Condition
Non-Small Cell Lung Cancer
Intervention
Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Why stopped
Grantor withdrew support due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-17